immunoSEQ: Adaptive’s first product
In March, 2010, Adaptive launched immunoSEQ, its first commercial product based on its technology.
ImmunoSEQ provides researchers an unparalleled ability to characterize the complete immune repertoire of a patient or group of patients in search of immunologic biomarkers.
Here’s how it works:
Step 1) The process begins with a phone call or email to an Adaptive scientific advisor who helps plan the experiment.
Step 2) Scientists send DNA, cDNA, tissue, or cell samples to Adaptive’s headquarters in Seattle, Washington.
Step 3) The samples undergo a ultrahigh-throughput sequence analysis.
Step 4) Scientists access their accounts from their own computers and use the immunoSEQ Analyzer, a powerful suite of software tools, to interpret and manipulate the data to discover meaningful information.
Researchers are using immunoSEQ in a wide range of applications as the technology is becoming the benchmark for immune profiling.
Drs. Carl June and Michael Kalos from the University of Pennsylvania published a set of marquee scientific papers in the New England Journal of Medicine and Science Translation Medicine that used the ImmunoSEQ assay to demonstrate the absence of cancer at a molecular level, based on a novel treatment approach.
To learn more about immunoSEQ, visit immunoseq.com